|
|
|
|
|
25.08.26 - 02:00
|
Element79 Gold Corp. And Synergy Metals Corp. Announce Completion Of Plan Of Arrangement And Merger (The Newswire)
|
|
|
VANCOUVER, BC - TheNewswire - August 24, 2026 – Element79 Gold Corp. (CSE: ELEM) (OTC: ELMGF) (FSE: 7YS) (“Element79”) and Synergy Metals Corp. (“Synergy”) are pleased to announce the successful completion of Element79's previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”) with Synergy and of Synergy's previously announced merger with 1425957 B.C. Ltd. (“142”).
Synergy is currently working diligently towards the listing of its Common Shares (as defined below) on the Canadian Securities Exchange (the “CSE”).
Arrangement
On July 17, 2023, Element79 transferred all rights and data related to the “Dale Property”, being 90 unpatented mining claims located approximately 100 km southwest of Timmins, Ontario, to its then newly incorporated subsidiary, Synergy. In exchange for this transfer, Element79 was issued 2,000,000 Class “A” common voting shares in the capital of Synergy, which were subsequently redes...
|
|
|
|
|
|
|
10.08.26 - 22:03
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 (Business Wire)
|
|
|
Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027
On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027
On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026
On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026
Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026.
“During the ...
|
|
|
05.08.26 - 17:06
|
GLP-1 muda gôndolas nos mercados e pão de queijo perde espaço (Bloomberg)
|
|
|
Nos supermercados brasileiros, o pão de queijo perde espaço para o iogurte. As redes varejistas estão reorganizando corredores e gôndolas para a era do Ozempic. Saiba mais com Rachel Gamarski. Edição de Patricia Xavier e produção de Barbara Nascimento e Catarina Bacci. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
19.05.26 - 14:12
|
EDP CEO on War Impact, Data Center Demand (Bloomberg)
|
|
|
Miguel Stilwell d'Andrade, CEO of Portuguese utility, EDP, discussed the impact of the Iran war on energy markets, a renewed push for European energy independence and growing demand for energy from data centers. Stilwell d'Andrade joined Anna Edwards, Guy Johnson and Tom Mackenzie on Bloomberg's The Opening Trade. (Source: Bloomberg)...
|
|
|
|
|
11.05.26 - 22:03
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 (Business Wire)
|
|
|
Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026
Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV)
On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026
Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2026.
“Since the inception of our immunology portfolio targeting type 2 diseases, our team ha...
|
|
|
|
|
|
|
|
|
30.04.26 - 22:03
|
Cerus Corporation Announces First Quarter 2026 Financial Results (Business Wire)
|
|
|
First Quarter 2026 Total Revenue of $59.9 million, Up 23% Over Prior Year; First Quarter 2026 Product Revenue of $53.7 million, Up 24% Over Prior Year
Raising Full Year Product Revenue Guidance Range to $227 million - $231 million, reflecting 10% to 12% year-over-year increaseCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update.
“We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our INTERCEPT Fibrinogen Complex,” said William “Obi” Greenman, Cerus' president and chief executive officer. “As a result, we are raising our product revenue guidance for the year. Looking ahead, we have a meaningful catalyst path in 2026, spanning anticipated regulatory, clinical, and pipeline milestones, including ongoing INTERCEPT RBC regulatory review in Europe, the Phase 3 RedeS readout in the U.S....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
